Drugs / BCR-ABL junction-specific peptide vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00428077 | Oct 2005 → Apr 2009 | leukemia | OHSU Knight Cancer Institute | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCR-ABL junction-specific peptide vaccine | “Patients receive BCR-ABL junction-specific peptide vaccine subcutaneously in weeks 2, 4, 6, 8, and 11 and then once monthly for 10 months.” NCT00428077 ↗ |
| Modality | Vaccine | “with a vaccine comprised of native and synthetic break-point cluster region-Abelson murine leukemia(BCR-ABL) specific peptides” NCT00428077 ↗ |
| Route | Subcutaneous | “BCR-ABL junction-specific peptide vaccine subcutaneously” NCT00428077 ↗ |